目次

1. Introduction To CD70 Targeting Therapy
1.1 CD70 Targeting Therapy Overview
1.2 The Prerequisite For CD70 Targeting Therapy
1.3 Dual Role of CD70 As Diagnostic and Prognostic Biomarker

2. CD70 Targeting Therapeutic Approaches
2.1 Monoclonal Antibody
2.2 Bispecific Antibody
2.3 Tetraspecific Antibody
2.4 CAR T Cell Therapy
2.5 Antibody Drug Conjugate
2.6 CAR-NK Therapy

3. CD70 Targeting Therapies Clinical Research and Development By Indications
3.1 Leukemia
3.2 Lymphoma
3.3 Gynecologic Cancer
3.4 Renal Cell Carcinoma
3.5 Lung Cancer
3.6 Autoimmune and Inflammatory Disease
3.7 Viral Infections

4. Global CD70 Targeting Therapies Clinical Trials Overview
4.1 By Phase
4.2 By Country
4.3 By Company
4.4 By Indication
4.5 By Priority Status
4.6 Patient Segment

5. CD70 Targeting Therapies Regulatory Designations: Fast Track and Orphan Designation

6. Global CD70 Targeting Therapies Clinical Trials Insight
6.1 Preclinical
6.2 Phase I
6.3 Phase I/II
6.4 Phase II

7. CD70 Targeting Therapies Development Platforms By Company and Technology
7.1 AlloCAR T Platform
7.2 Gamma Delta Cell Platform
7.3 Tailwind Platform
7.4 DARPin Platform
7.5 SIMPLE Antibody Platform
7.6 Potelligent Technology
7.7 Off The Shelf Allogeneic Manufacturing

8. Global CD70 Targeting Therapies Current Market Trend and Developments
8.1 Current Market Outline
8.2 Future Market Forecast

9. CD70 Targeting Therapies Market Opportunity and Clinical Trends By Region
9.1 US
9.2 China
9.3 Europe

10. Combination Strategies For CD70 Targeting Therapies
10.1 In Combination With Immunotherapy
10.2 In Combination With Epigenetic Modulators
10.3 In Combination With Targeted Therapy
10.4 In Combination With Oncolytic Virus Therapy
10.5 In Combination With Chemotherapy

11. Global CD70 Targeting Therapies Market Dynamics
11.1 Market Drivers
11.2 Market Challenges

12. Competitive Landscape
12.1 Adaptimmune
12.2 Adicet Bio
12.3 Allogene Therapeutics
12.4 Ambrx (Johnson and Johnson)
12.5 Chongqing Precision Biotech
12.6 Chinook Therapeutics (Novartis)
12.7 CRISPR Therapeutics
12.8 ImmuneOnco Biopharma
12.9 Pfizer
12.10 Poseida Therapeutics

List of Figures
Figure 1-1: Introduction To CD70 Protein
Figure 1-2: History and Development Of CD70 Targeting Therapies
Figure 1-3: CD70 As Diagnostic and Prognostic Marker In Cancer
Figure 2-1: Approaches For Targeting CD70
Figure 3-1: Role Of CD70 In Leukemia
Figure 3-2: Molecular Partners - MP0533
Figure 3-3: MP0533 Phase I/II (NCT05673057) Study - Initiation and Completion Year
Figure 3-4: Cusatuzumab Phase II (NCT04023526) Study - Initiation and Completion Year
Figure 3-5: Cusatuzumab Phase II (NCT06384261) Study - Initiation and Completion Year
Figure 3-6: Role Of CD70 In Leukemia
Figure 3-7: CAR.70/IL-15 NK Cell Therapy Phase II (NCT05092451) Study - Initiation and Completion Year
Figure 3-8: CB CAR-NK019 Phase I (NCT05667155) Study - Initiation and Completion Year
Figure 3-9: CD70 CAR T Therapy Early Phase I (NCT04662294) Study - Initiation and Completion Year
Figure 3-10: Lymphoma: Key Market Players Conducting CD70 Clinical Research
Figure 3-11: Role Of CD70 In Gynecologic Cancers
Figure 3-12: CD70 CAR-T Therapy Phase I (NCT06010875) Study - Initiation and Completion Year
Figure 3-13: Anti-hCD70 CAR transduced PBL Phase I/II Study - Initiation and Completion Year
Figure 3-14: CTX131 Phase I (NCT05795595) Study - Initiation and Completion Year
Figure 3-15: Role Of CD70 In Renal Cell Carcinoma
Figure 3-16: Research By Allogene Therapeutics
Figure 3-17: TRAVERSE Phase 1 (NCT04696731) Study - Initiation and Completion Year
Figure 3-18: CTX131 Phase I/II (NCT05795595) Study - Initiation and Completion Year
Figure 3-19: CTX131 Phase I/II (NCT05795595) Study - Initiation and Completion Year
Figure 3-20: Role Of CD70 In Lung Cancer
Figure 3-21: Role Of CD70 In Autoimmune and Inflammatory Diseases
Figure 3-22: Role Of CD70 In Autoimmune and Inflammatory Diseases
Figure 4-1: Global - CD70 Targeting Therapies Clinical Trials By Phase (Numbers), 2025
Figure 4-2: Global - CD70 Targeting Therapies Clinical Trials By Country (Numbers), 2025
Figure 4-3: Global - CD70 Targeting Therapies Clinical Trials By Company (Numbers), 2025
Figure 4-4: Global - CD70 Targeting Therapies Clinical Trials By Indication (Numbers), 2025
Figure 4-5: Global - CD70 Targeting Therapies Clinical Trials By Priority Status (Numbers), 2025
Figure 4-6: Global - CD70 Targeting Therapies Clinical Trials By Patient Segment (Numbers), 2025
Figure 7-1: Allogene Therapeutics - AlloCAR T Platform
Figure 7-2: Adicet Bio - Gamma Delta Cell Platform
Figure 7-3: ADI-270 - CD70 CAR andgamma;anddelta; T Cell Therapy
Figure 7-4: Catamaran Bio - Tailwind Platform
Figure 7-5: Molecular Partners - DARPin Platform
Figure 7-6: Nkarta - CAR-NK Cells
Figure 7-7: Nkarta - Proprietary CAR-NK Cells Manufacturing Process
Figure 8-1: CD70 Targeting Therapy Current Market - Guiding Factors
Figure 8-2: Key Players In CD70 Market
Figure 8-3: CD70 Targeting Therapy Market Future - Influencing Factors
Figure 10-1: Combinations Of CD70 Therapy With Other Therapies
Figure 11-1: Global CD70 Targeting Therapy Market - Drivers
Figure 11-2: Global CD70 Targeting Therapy Market - Challenges

List of Tables
Table 6-1: CD70 Targeting Therapies With Regulatory Designations